

EFFECTIVENESS, SAFETY AND INCREMENTAL COSTS OF PROACTIVE THERAPEUTIC DRUG MONITORING OF INFLIXIMAB IN A REAL-LIFE COHORT OF INFLAMMATORY BOWEL DISEASE PATIENTS

Dusan Podmanicky

UEG Week Copenhagen 2023

Poster

IBD

October 15, 2023

A real-world study of 99 IBD patients found that proactive therapeutic drug monitoring of infliximab achieved 60% treatment persistence beyond two years, with incremental first-year costs of €661 per patient compared to a modelled reactive monitoring approach.

KEY POINTS

- Treatment persistence with proactive monitoring was 87% at 6 months, 77% at one year, 66% at two years, and 60% at three and four years in a cohort starting infliximab between 2018 and 2021
- Treatment was intensified in 58% of patients using a 3 µg/ml trough level cut-off measured at week 14 and every six months thereafter
- No differences in adverse events were observed between patients on conventional versus intensified treatment regimens
- Proactive monitoring added €65,460 in total costs for 99 patients over one year compared to a modelled reactive approach, equating to €661 per patient
- The study provides real-world cost and effectiveness data for proactive therapeutic drug monitoring in an IBD population predominantly with Crohn's disease

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/1cc12718-743d-11ee-8b29-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.